Show simple item record

dc.contributor.authorChen, R
dc.contributor.authorZinzani, P
dc.contributor.authorFanale, M
dc.contributor.authorArmand, P
dc.contributor.authorJohnson, N
dc.contributor.authorBrice, P
dc.contributor.authorRadford, John A
dc.contributor.authorRibrag, V
dc.contributor.authorMolin, D
dc.contributor.authorVassilakopoulos, T
dc.contributor.authorTomita, A
dc.contributor.authorvon Tresckow, B
dc.contributor.authorShipp, M
dc.contributor.authorZhang, Y
dc.contributor.authorRicart, A
dc.contributor.authorBalakumaran, A
dc.contributor.authorMoskowitz, C
dc.date.accessioned2017-05-16T08:53:34Z
dc.date.available2017-05-16T08:53:34Z
dc.date.issued2017-04-25
dc.identifier.citationPhase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. 2017, J Clin Oncolen
dc.identifier.issn1527-7755
dc.identifier.pmid28441111
dc.identifier.doi10.1200/JCO.2016.72.1316
dc.identifier.urihttp://hdl.handle.net/10541/620367
dc.description.abstractPurpose Hodgkin Reed-Sternberg cells harbor alterations in chromosome 9p24.1, leading to overexpression of programmed death-ligand 1 (PD-L1) and PD-L2. Pembrolizumab, a programmed death 1-blocking antibody, demonstrated a high overall response rate (ORR) in patients with relapsed or refractory classic Hodgkin lymphoma (rrHL) in phase I testing. Methods KEYNOTE-087 ( ClinicalTrials.gov identifier, NCT02453594) was a single-arm phase II study of pembrolizumab in three cohorts of patients with rrHL, defined on the basis of lymphoma progression after (1) autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV); (2) salvage chemotherapy and BV, and thus, ineligible for ASCT because of chemoresistant disease; and (3) ASCT, but without BV after transplantation. Patients received pembrolizumab 200 mg once every 3 weeks. Response was assessed every 12 weeks. The primary end points were ORR by central review and safety. Results A total of 210 patients were enrolled and treated (69 in cohort 1, 81 in cohort 2, and 60 in cohort 3). At the time of analysis, patients received a median of 13 treatment cycles. Per central review, the ORR was 69.0% (95% CI, 62.3% to 75.2%), and the complete response rate was 22.4% (95% CI, 16.9% to 28.6%). By cohort, ORRs were 73.9% for cohort 1, 64.2% for cohort 2, and 70.0% for cohort 3. Thirty-one patients had a response ≥ 6 months. The safety profile was largely consistent with previous pembrolizumab studies. Conclusion Pembrolizumab was associated with high response rates and an acceptable safety profile in patients with rrHL, offering a new treatment paradigm for this disease.
dc.language.isoenen
dc.rightsArchived with thanks to Journal of clinical oncology : official journal of the American Society of Clinical Oncologyen
dc.titlePhase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma.en
dc.typeArticleen
dc.contributor.departmentRobert Chen, City of Hope National Medical Center, Duarte, CAen
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.collectionLymphoma Research Teamen
refterms.dateFOA2017-11-16T00:00:00Z
html.description.abstractPurpose Hodgkin Reed-Sternberg cells harbor alterations in chromosome 9p24.1, leading to overexpression of programmed death-ligand 1 (PD-L1) and PD-L2. Pembrolizumab, a programmed death 1-blocking antibody, demonstrated a high overall response rate (ORR) in patients with relapsed or refractory classic Hodgkin lymphoma (rrHL) in phase I testing. Methods KEYNOTE-087 ( ClinicalTrials.gov identifier, NCT02453594) was a single-arm phase II study of pembrolizumab in three cohorts of patients with rrHL, defined on the basis of lymphoma progression after (1) autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV); (2) salvage chemotherapy and BV, and thus, ineligible for ASCT because of chemoresistant disease; and (3) ASCT, but without BV after transplantation. Patients received pembrolizumab 200 mg once every 3 weeks. Response was assessed every 12 weeks. The primary end points were ORR by central review and safety. Results A total of 210 patients were enrolled and treated (69 in cohort 1, 81 in cohort 2, and 60 in cohort 3). At the time of analysis, patients received a median of 13 treatment cycles. Per central review, the ORR was 69.0% (95% CI, 62.3% to 75.2%), and the complete response rate was 22.4% (95% CI, 16.9% to 28.6%). By cohort, ORRs were 73.9% for cohort 1, 64.2% for cohort 2, and 70.0% for cohort 3. Thirty-one patients had a response ≥ 6 months. The safety profile was largely consistent with previous pembrolizumab studies. Conclusion Pembrolizumab was associated with high response rates and an acceptable safety profile in patients with rrHL, offering a new treatment paradigm for this disease.


Files in this item

Thumbnail
Name:
JCO.2016.72.pdf
Size:
747.8Kb
Format:
PDF
Description:
Full text

This item appears in the following Collection(s)

Show simple item record